The breakthrough came after the investment group provided France with guarantees on maintaining jobs and production in the ...

Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies for rare cancers, ...

Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare ...

(IN BRIEF) Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare cancers. By combining their expertise, they aim to advance ...

Both Sanofi and Orano Med are part of the Paris Saclay cancer cluster and are committed to supporting the France 2030 plan's ...

The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 ...

In a new study examining people with opioid or alcohol use disorder, prescriptions for Ozempic, Wegovy, Mounjaro, and ...

Sanofi & Orano join forces to accelerate the development of develop next-generation radioligand medicines: Paris Friday, October 18, 2024, 10:00 Hrs [IST] Sanofi and Orano Med, a ...

The investment will support development of radioligand therapies for cancer based on lead-212 alpha-emitting isotopes.

Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...

Sanofi and Orano join forces to develop next-generation radioligand medicinesParis, October 17, 2024. Sanofi and Orano Med, a subsidiary of the ...

Sanofi has partnered with Orano Med, a subsidiary of Orano Group, to develop radioligand therapies for rare cancers. Sanofi ...